With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from ...

Scientists have developed a breakthrough therapy that could revolutionise the treatment of high cholesterol, which currently ...

A preclinical study presented at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), held in ...

A new DNA-based therapy could cut cholesterol nearly in half—without relying on statins or causing side effects.

Researchers have unveiled a new DNA-based therapy that silences the PCSK9 gene to lower cholesterol without statin side effects. Early results show dramatic reductions in cholesterol levels, offering ...

Discover how cholesterol-lowering drug targets may reduce dementia risk through genetic insights. Keep reading.

An expert discusses how nonstatin therapies serve as essential tools when patients can’t tolerate statins or need additional ...

Cardiologists often struggle to assess heart attack risk. New startups using AI could help.

CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...